Synaptogenix (NASDAQ:TAOX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Synaptogenix (NASDAQ:TAOX) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Synaptogenix has an average rating of “Sell”.

Synaptogenix Price Performance

Shares of Synaptogenix stock opened at $4.35 on Friday. The stock’s 50-day moving average is $3.79 and its 200 day moving average is $4.37. Synaptogenix has a one year low of $3.07 and a one year high of $10.00. The firm has a market cap of $32.54 million, a price-to-earnings ratio of -1.13 and a beta of 1.49.

Synaptogenix (NASDAQ:TAOX) last issued its earnings results on Thursday, August 13th. The company reported ($1.83) earnings per share for the quarter. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.The business had revenue of $0.09 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc and adopted the Synaptogenix name as part of a corporate rebranding.